BIIB
$BIIB
Biogen Inc.
Biotech company developing therapies for neurological diseases including Alzheimer's and MS.
HealthcareSubscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
BIIB: Apellis Deal Reshapes Growth, Near-Term Headwinds
Biogen's $5.6B Apellis acquisition adds commercial revenue and rare disease assets, while a $34M R&D charge trims near‑term earnings. Analysts remain generally positive, but integration and reimbursement risks keep the view cautious.
Apr 6, 2026